With 0.16 million shares changed hands, the volume of the stock remained heavier than its average volume of 66180.0 shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $23.235 whereas the lowest price it dropped to was $22.55. The 52-week range on TBRG shows that it touched its highest point at $23.32 and its lowest point at $7.55 during that stretch. It currently has a 1-year price target of $20.00. TBRG paid its most recent dividend on 1597363200, while the ex-dividend date for that was 1597363200. Beta for the stock currently stands at 0.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TBRG was up-trending over the past week, with a rise of 7.15%, but this was up by 28.39% over a month. Three-month performance surged to 78.44% while six-month performance rose 113.10%. The stock gained 135.66% in the past year, while it has gained 16.28% so far this year. A look at the trailing 12-month EPS for TBRG yields -4.09 with Next year EPS estimates of 0.23. For the next quarter, that number is -0.03. This implies an EPS growth rate of 69.69% for this year and 123.61% for next year.
Float and Shares Shorts:
At present, 14.93 million TBRG shares are outstanding with a float of 14.34 million shares on hand for trading. On 2024-12-31, short shares totaled 0.26 million, which was 176.0 higher than short shares on 1732838400. In addition to Mr. Christopher L. Fowler as the firm’s CEO, President & Director, Mr. Wes D. Cronkite serves as its Chief Technology & Innovation Officer.
Institutional Ownership:
Through their ownership of 0.71636003 of TBRG’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, TBRG reported revenue of $83830000.0 and operating income of $1944000.0. The EBITDA in the recently reported quarter was $8030000.0 and diluted EPS was -$0.66.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TBRG since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TBRG analysts setting a high price target of 24.0 and a low target of 15.0, the average target price over the next 12 months is 20.0. Based on these targets, TBRG could surge 4.67% to reach the target high and fall by -34.58% to reach the target low. Reaching the average price target will result in a decline of -12.78% from current levels.
Analysts have provided yearly estimates in a range of -$0.43651 being high and -$1.47321 being low. For TBRG, this leads to a yearly average estimate of -$0.95486. Based on analyst estimates, the high estimate for the next quarter is $0.36 and the low estimate is $0.19. The average estimate for the next quarter is thus $0.29.
